Chondroitin Sulfate Market Report 2026

The chondroitin sulfate market size has grown strongly in recent years. It will grow from $1.48 billion in 2025 to $1.57 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to growth in osteoarthritis prevalence, increasing demand for dietary supplements, expansion of pharmaceutical manufacturing, rising use in pet nutrition products, availability of animal-derived raw materials.

The chondroitin sulfate market size is expected to see strong growth in the next few years. It will grow to $1.93 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing aging population, rising awareness of joint health supplements, expansion of nutraceutical markets, growing demand for clean-label ingredients, increasing investments in synthetic chondroitin production. Major trends in the forecast period include increasing use of chondroitin in joint health supplements, rising demand for animal-derived active ingredients, growing adoption in veterinary nutrition, expansion of cosmetic grade chondroitin, enhanced focus on purity and traceability.

The rising prevalence of osteoarthritis is expected to drive the growth of the chondroitin sulfate market. Osteoarthritis is a common form of arthritis affecting millions worldwide, occurring when the protective cartilage cushioning the ends of bones gradually deteriorates. Chondroitin sulfate helps treat osteoarthritis by providing resistance to compression, maintaining structural integrity, supporting homeostasis, slowing degeneration, and alleviating muscular pain. For instance, in October 2025, NHS Inform, a Scotland-based national health information service, reported that over 500,000 individuals annually require hospital care due to fragility fractures, which result from osteoporosis and often occur from a fall at standing height or lower. Therefore, the increasing incidence of osteoarthritis is boosting demand for chondroitin sulfate.

Leading companies in the chondroitin sulfate market are developing advanced solutions, such as multi-ingredient formulations, to enhance joint support, improve mobility, and promote musculoskeletal wellness. Multi-ingredient formulations combine chondroitin sulfate with complementary compounds like collagen type II and hyaluronic acid to provide synergistic benefits for joint function. For example, in October 2024, Symrise, a Germany-based producer of ingredients and solutions for the flavor, fragrance, and nutrition sectors, launched Chondractiv Plus, which features collagen-rich hydrolyzed chicken cartilage powder. This product contains collagen type II, chondroitin sulfate, hyaluronic acid, and proteins, with a recommended daily dosage of 1.5 grams to support joint health. Designed for dietary supplements and functional foods, Chondractiv Plus offers a sustainable 3-in-1 hydrolyzed solution that integrates natural ingredients with taste-balancing for an enhanced consumer experience while providing science-backed support for active lifestyles.

In November 2024, Borsch Med Pte Ltd, a Singapore-based healthcare and nutrition company, partnered with Zeria Pharmaceutical Co. Ltd. to expand access to chondroitin-based joint health supplements. Through this collaboration, Borsch Med aims to provide elderly consumers with improved access to Zeria’s joint health products, supporting healthier aging in the region. Zeria Pharmaceutical Co., Ltd. is a Japan-based company specializing in chondroitin-based joint health solutions.

Major companies operating in the chondroitin sulfate market are Seikagaku Corporation, Synutra Ingredients, TSI Group Ltd., Sioux Pharm, Summit Nutritionals International Inc., ZPD A/S, Sino Siam Bio technique Co. Ltd., Bio-gen Extracts Pvt. Ltd., Hebei Sanxin industry Group Co.Ltd., Fidia Farmaceutici S.p.A., Gnosis S.p.A., Pacific Rainbow International Inc., Bioiberica S.A.U., Ruikangda Biochemical Co. Ltd., Guanglong Biochem Co. Ltd., Nippon Zoki Pharmaceutical Co. Ltd., Huiwen Technology Co. Ltd., Runxin Biotechnology Co. Ltd., WanTuMing Biological, QJBCHINA, Hengjie Bio-Pharmaceuticals, Rochem International Inc., Chongqing Aoli Biopharmaceutical Co. Ltd.

North America was the largest region in the chondroitin sulfate market in 2025. Asia-Pacific is expected to be the fastest-growing region in the chondroitin sulfate market report during the forecast period. The regions covered in the chondroitin sulfate market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chondroitin sulfate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chondroitin sulfate market consists of sales of glucuronic acid and N-acetylga-lactosamine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.